RxDoctor Payments Data

Kimberly Holmes

Family · Winchester, VANPI 1982372447

Payments from drug & device makers

$5,777in general payments, 2019–2025

Across 293 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$682
  • UCB, Inc.$297
  • EMD Serono, Inc.$265
  • AstraZeneca$258
  • Lundbeck LLC$243
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$5,55496%
  • Education$2224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,777 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$59,450
Medicare patients
219
Services billed
4,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5018$407,890
VumerityDiroximel Fumarate17$170,360
Kesimpta PenOfatumumab12$133,807
UbrelvyUbrogepant35$64,811
QuliptaAtogepant28$29,706
Emgality PenGalcanezumab-Gnlm26$26,292
Nurtec OdtRimegepant Sulfate11$18,235
Aimovig AutoinjectorErenumab-Aooe19$13,950
Teriflunomide14$11,383
FingolimodFingolimod Hcl24$7,186
Baclofen129$4,314
Tegretol XrCarbamazepine11$4,262
Pregabalin142$4,167
Gabapentin199$3,508
Carbamazepine ErCarbamazepine29$3,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$52$407,89018 claims
BiogenVumerity$682$170,36017 claims
AbbVieUbrelvy, Qulipta$1,053$94,51863 claims
PfizerNurtec Odt$242$18,23511 claims
Upsher-smith Laboratories LLCTopiramate$20$42241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →